Alkermes came through its second quarter with the balance sheet of one company and the ambition of another. A neuroscience compounder built on four commercial products - VIVITROL, ARISTADA, LYBALVI and, as of February, LUMRYZ - it closed the $2.3 billion acquisition of Avadel in February, borrowed nearly $1.5 billion to do it, and tied its future to a single idea: that wakefulness is a large, under-served market and Alkermes intends to own it. The quarter showed both sides of that bet. Total revenue rose 27% to $496 million, but nearly a fifth of it was LUMRYZ, which did not exist in the comparison. Stripped of the acquisition, underlying product sales grew only about 3%. GAAP net income collapsed to $0.5 million from $87 million a year earlier as amortization, acquisition costs and a fair-value charge rolled through.
The result is a company spending its near-term GAAP profitability - and a chunk of its clean balance sheet - to underwrite the orexin franchise it sees as transformational. Adjusted EBITDA, the measure management highlights, rose 10% to $139 million even as GAAP operating income fell 80% on one-time items. The stock has already moved: it roughly doubled off its 2025 low to July highs in the mid-$50s before settling near $50, a market that has largely accepted the sleep-acquisition and re-rated the pipeline. The question the next two quarters answer is whether the acquired LUMRYZ franchise compounds as promised, and whether alixorexton, the orexin asset the whole strategy is built to launch, converts early promise into the data the company has scheduled.